PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
about
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityLRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site statusDown-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicityFunctional neuroimaging in Parkinson's diseaseManganism in the 21st century: the Hanninen lectureEnhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SCerebrospinal fluid amyloid β and tau in LRRK2 mutation carriersThe role of biomarkers and imaging in Parkinson's disease.Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.Neuroimaging in pre-motor Parkinson's diseaseLeucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's diseaseNeuroimaging: current role in detecting pre-motor Parkinson's disease.Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.Dopaminergic neuronal loss and dopamine-dependent locomotor defects in Fbxo7-deficient zebrafish.Genetics of Parkinson's disease: LRRK2 on the rise.Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesisThe nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applicationsThe Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit functionMolecular imaging in hereditary forms of parkinsonism.Genetics of Parkinson disease.Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.Normal dopaminergic nigrostriatal innervation in SPG3A hereditary spastic paraplegia.LRRK2 in Parkinson's disease: genetic and clinical studies from patients.Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?Imaging dopamine transporters in Parkinson's disease.Milestones in neuroimaging.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.Positron emission tomography neuroimaging in Parkinson's disease.
P2860
Q22254785-27B43211-397C-4C04-8B72-83FD1650B9C1Q24300605-45A51CDD-5284-41D8-91AC-FBA329870785Q24339471-D7DDB4FE-5C77-4C48-B687-89E8060695E5Q27013767-AE1E1CB1-88D4-4399-B2B8-25CF516060B9Q27015750-FF11DB08-C77F-49B1-8998-7AE9488EB698Q28589899-B94187BF-12D5-44E1-8D43-718883D6BCE5Q30525550-E991149B-1348-4F7F-8D2E-990DB533689BQ31041660-87ACA414-7620-47C8-9C6F-DB4EA1643834Q31158920-1EF2F305-A72A-487E-9554-70E0A6ADA0BFQ33668068-13CF90AD-3A34-4D27-B35A-2559D260D420Q33676222-2E91993E-ED70-4669-9793-0832A1085581Q33812599-3F300397-AF22-4B0B-BDB3-9313F4186218Q34234625-C500A3DE-2509-42AB-A157-C89E96737B41Q34234632-33D3FA78-BED5-4ED3-84ED-4E6D76DA3C8FQ34469890-A8EA7C22-A62F-4EE9-8908-39DE5B3AD97DQ34470633-B0860D8E-2950-4B4B-ABA3-A36A22B79DF2Q34540567-380FE8FD-D3B8-48A8-9858-B8A976C72D13Q34553777-CE743CDD-1BFF-4AD1-9EDD-887EF1654B6CQ34919409-19090B70-1DD5-41FF-8D60-44A4BAA0FEEDQ35034718-310CAED6-9097-4690-B62F-DFF9D8E94A97Q35106295-D1487BDB-F37E-4207-BE7B-AAB9293E794EQ35148581-CECFF916-C2D0-4094-984B-10A5484FBFA4Q35235888-F8529CEF-362D-40D5-9DFF-1A8856B2FD3CQ35614156-E370AC25-1FED-42D9-A8CB-8364294FB1A9Q35757332-11ACC148-26CC-4AD3-AEB5-B89DE930997BQ36345908-09C2ED25-44A1-4006-B29A-3827A8A34EFBQ36553302-39475138-18FA-4CDA-BCDA-CB5F51AA6730Q36581417-67BB6524-7704-4F10-B3E7-126796C668B5Q36771898-B71769DF-4199-47BE-8460-D84D7226F5A2Q37037053-C378881E-97E8-41BD-8DFE-398FD58405ABQ37243261-0598AC81-BC86-4580-92FE-131C90A09207Q37313530-B9155136-7131-4696-9629-80412425E730Q37344742-BD3484D0-3863-45D7-A50A-ADEA5DC37FB3Q37608624-FE918514-6524-40B9-990B-E1D48E1F26F8Q37679384-3792C213-EAF1-4E9D-9263-C63CD59A8D3AQ37712626-70DEB395-2878-4BD7-B69E-23AE96E7A0F7Q37800096-DFC206B6-37BE-42C2-8F75-FF7AB1DD6895Q37882576-FD250DB4-1D01-42B5-BDC6-B05D3562C250Q37910636-0F78F4D5-5BC8-4E6E-A1B0-D64ACF08449AQ37929598-EC2FF57D-D353-4831-843C-A60E8C6890D8
P2860
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@en
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@nl
type
label
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@en
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@nl
prefLabel
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@en
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@nl
P2093
P2860
P50
P356
P1433
P1476
PET in LRRK2 mutations: compar ...... r presymptomatic compensation.
@en
P2093
A Jon Stoessl
Audrey Strongosky
Chong S Lee
Hinke van Netten
Jessamyn Mckenzie
John R Adams
Michael Schulzer
Thomas J Ruth
P2860
P304
P356
10.1093/BRAIN/AWH607
P407
P577
2005-08-04T00:00:00Z